Continuing a busy period of dealmaking, pharma major AstraZeneca (LSE: AZN) has confirmed it will buy vaccine specialist Icosavax (Nasdaq: ICVX) for around $800 million.
In recent weeks, Britain’s largest drugmaker has announced a new AI-based collaboration, a cell therapy partnership in China, the launch of a digital health company and the acquisition of rights to a novel KRAS blocker.
The latest deal will see the company augment its newly-established vaccines experience with the integration of an American biotech focused on an innovative, protein virus-like particle (VLP) platform.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze